当前位置: 首页 > 期刊 > 《医药产业资讯》 > 2010年第11期
编号:11899074
支气管哮喘的药物治疗成就及前景(2)
http://www.100md.com 2010年4月15日 《中国医药导报》 2010年第11期
     [2]Grainger J, Woodman K, Pearce N, et al. Prescribed Fenoterol and death from asthma in New Zealand,1981-87: a further case-control study [J]. Thorax,1991,46(8):105-111.

    [3]Diaz P, Gonzalez MC, Gallcguillos FR, et al. Leukocytes and mediators in bronchoalveolar lavage during allergen-induced late phase asthmatic reactions [J]. Am Rev Respir Dis,1989,139(6):1383-1389.

    [4]李长保.不同方案雾化吸入治疗支气管哮喘临床对比分析[J].中国当代医药,2009,16(23):50,52.

    [5]Djukanovie R. Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma [J]. Am Rev Respir Dis,1992,142(3):669-674.

    [6]Meltzer DL, Kemp JP. Beta2-agonists: pharmacology and recent developments [J]. J Asthma,1991,28(3):179-186.

    [7]Gross NJ. Ipratropium bromide [J]. N Engl J Med,1988,319(8):486-494.

    [8]Weinberger, M, Hendeles L. Theophylline in asthma [J]. N Engl J Med,1996,327(21):1380-1388.

    [9]Page CP, Metzger WJ. Drugs and the lung [M]. New York: Raven Press,1994.

    [10]Smith LJ. Leukotrienes in asthma, the potential therapeutic role of antileukotriene agents [J]. Arch Inter Med,1996,156(19):2181-2189.

    [11]Schudt C, Tenor H, Hatzelmann A. PDE isoenzymes as targets for anti-asthma drugs [J]. Eur Respir J,1995,39(8):1179-1183.

    [12]Marone G. Asthma: recent advances [J]. Immunology Today,1998,19(1):5-9.

    (收稿日期:2010-01-11), 百拇医药(叶 艳)
上一页1 2